Randomized crossover study to examine the necessity of an injection-to-meal interval in patients with type 2 diabetes and human insulin

Nicolle Müller, Thomas Frank, Christof Kloos, Thomas Lehmann, Gunter Wolf, Ulrich Alfons Müller, Nicolle Müller, Thomas Frank, Christof Kloos, Thomas Lehmann, Gunter Wolf, Ulrich Alfons Müller

Abstract

Objective: Patients with diabetes and insulin therapy with human insulin were usually instructed to use an interval of 20-30 min between the injection and meal. We examined the necessity of the injection-to-meal interval (IMI) in patients with type 2 diabetes mellitus (T2DM) and flexible insulin therapy with human insulin.

Research design and methods: In this randomized, open crossover trial, 100 patients with T2DM (47% men, mean age = 66.7 years) were randomized to the IMI first group (phase 1, IMI 20 min; phase 2, no IMI) or IMI last group (phase 1, no IMI; phase 2, IMI 20 min). The main outcome measures were HbA1c, blood glucose profile, incidence of hypoglycemia, quality of life, treatment satisfaction, and patient preference.

Results: Forty-nine patients were randomized to the IMI first group and 51 patients to the IMI last group. Omitting the IMI only slightly increases HbA1c (average intraindividual difference = 0.08% [95% CI 0.01-0.15]). Since the difference is not clinically relevant, a therapy without IMI is noninferior to its application (P < 0.001). In the secondary outcomes, the incidence of mild hypoglycemia also did not differ between no IMI and IMI significantly (mean of differences = -0.10, P = 0.493). No difference in the blood glucose profile of both groups was found. Treatment satisfaction increased markedly, by 8.08, if IMI was omitted (P < 0.001). The total score of the quality of life measure did not show differences between applying an IMI or not. Insulin therapy without IMI was preferred by 86.5% of patients (P < 0.001).

Conclusions: An IMI for patients with T2DM and preprandial insulin therapy is not necessary.

Trial registration: ClinicalTrials.gov NCT00529165.

Figures

Figure 1
Figure 1
Study design. (A high-quality color representation of this figure is available in the online issue.)
Figure 2
Figure 2
Blood glucose profiles (mean) of phase without IMI and phase with IMI.

References

    1. Statistisches Bundesamt, Robert-Koch-Institut: Gesundheitsberichterstattung des Bundes: Germany [Internet], 2006. Available from Accessed 28 March 2012
    1. Hansen B, Altenhofen L, Haß W, Blaschy S, Kretschmann J. Report of the Disease Management Programmes 2007 in North Rhine: breast cancer, diabetes mellitus type 2, coronary artery disease, asthma, and COPD [Internet], 2008. KV North Rhine. Available from Accessed 28 March 2012
    1. Galloway JA, Spradlin CT, Nelson RL, Wentworth SM, Davidson JA, Swarner JL. Factors influencing the absorption, serum insulin concentration, and blood glucose responses after injections of regular insulin and various insulin mixtures. Diabetes Care 1981;4:366–376
    1. Berger M, Cüppers HJ, Hegner H, Jörgens V, Berchtold P. Absorption kinetics and biologic effects of subcutaneously injected insulin preparations. Diabetes Care 1982;5:77–91
    1. Müller N, Kloos C, Frank T, Ristow M, Wolf G, Müller UA. Prevalence of injection-meal interval usage and its association with variables of metabolic control in patients with type 1 and type 2 diabetes. Diabet Med 2011;28:223–226
    1. Overmann H, Heinemann L. Injection-meal interval: recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract 1999;43:137–142
    1. Ahmad ABE, Badgandi M, Home PD. Interval between insulin injection and meal in relation to glycated haemoglobin. Pract Diabetes Int 2001;18:51–56
    1. Davidson JK, Fineberg SE, De Meyts P, Fineberg NS, Galloway JA. Immunological and metabolic responses of patients with history of antibody-induced beef insulin resistance to treatment with beef, pork, human, and sulfated beef insulin. Diabetes Care 1992;15:702–704
    1. Kinmonth AL, Baum JD. Timing of pre-breakfast insulin injection and postprandial metabolic control in diabetic children. BMJ 1980;280:604–606
    1. Witt MF, White NH, Santiago JV. Roles of site and timing of the morning insulin injection in type 1 diabetes. J Pediatr 1983;103:528–533
    1. Dimitriadis GD, Gerich JE. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 1983;6:374–377
    1. Lean ME, Ng LL, Tennison BR. Interval between insulin injection and eating in relation to blood glucose control in adult diabetics. Br Med J (Clin Res Ed) 1985;290:105–108
    1. Bolli GB. Clinical strategies for controlling peaks and valleys: type 1 diabetes. Int J Clin Pract Suppl 2002;129:65–74
    1. Kautzky-Willer A. Are “designer” insulins the “best” insulins? Wien Klin Wochenschr 2005;117:571–575 [in German]
    1. Brunton S. Initiating insulin therapy in type 2 diabetes: benefits of insulin analogs and insulin pens. Diabetes Technol Ther 2008;10:247–256
    1. Müller UA, Femerling M, Reinauer KM, et al. ASD (the Working Group on Structured Diabetes Therapy of the German Diabetes Association) Intensified treatment and education of type 1 diabetes as clinical routine. A nationwide quality-circle experience in Germany (Abstract). Diabetes Care 1999;22(Suppl. 2):B29–B34
    1. Bradley C, Todd C, Gorton T, Symonds E, Martin A, Plowright R. The development of an individualized questionnaire measure of perceived impact of diabetes on quality of life: the ADDQoL. Qual Life Res 1999;8:79–91
    1. Bradley C. The diabetes treatment satisfaction questionnaire: DTSQ. In Handbook of Psychology and Diabetes: A Guide to Psychological Measurements in Diabetes Research and Practice. Bradley C, Ed. Chur, Switzerland, Harwood Academic Publishers, 1994
    1. Bradley C. Diabetes treatment satisfaction questionnaire. Change version for use alongside status version provides appropriate solution where ceiling effects occur. Diabetes Care 1999;22:530–532
    1. Scheen AJ, Letiexhe MR, Lefèbvre PJ. Minimal influence of the time interval between injection of regular insulin and food intake on blood glucose control of type 1 diabetic patients on a basal-bolus insulin scheme. Diabetes Metab 1999;25:157–162
    1. Reise K, Hartung V, Lehmann T, et al. Frequency of severe and nonsevere hypoglycaemia and difficulties at workplace in patients with insulin-treated diabetes mellitus (Abstract). Diabetologia 2011;54(Suppl. 1):654
    1. Ashwell SG, Bradley C, Stephens JW, Witthaus E, Home PD. Treatment satisfaction and quality of life with insulin glargine plus insulin lispro compared with NPH insulin plus unmodified human insulin in individuals with type 1 diabetes. Diabetes Care 2008;31:1112–1117
    1. Gale EAM, The UK Trial Group A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with type 1 diabetes on intensified insulin therapy. Diabet Med 2000;17:209–214
    1. Siebenhofer A, Plank J, Berghold A, et al. Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. In The Cochrane Library Issue 1. Chichester, U.K., John Wiley & Sons Ltd., 2010

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever